Skip to main content

Modeling Differential Patient Responses to B Cell Elimination with S15-DKO

Published Date

Engraftment of peripheral blood mononuclear cells from individual donors into S15-DKO mice provides a powerful platform to investigate patient-specific responses to immunotherapies. Dr. Kennedy is using this model to evaluate tri-specific killer engagers (TriKEs)—novel biologics designed to activate natural killer cells—in the settings of lupus and B cell lymphoma. By examining donor-to-donor variation in the elimination of malignant or pathogenic B cells, this work seeks to inform clinical development of natural killer cell–based therapies.

Topics we will cover:

  • Immune heterogeneity in patients that shapes the composition of humanized S15-DKO mouse models
  • The new S15-DKO model as it supports robust engraftment and maturation of human B cells, enabling investigation of B cell-driven pathology
  • How functional human NK cells are maintained in the S15-DKO model, providing a translational platform to evaluate NK cell-mediated immunotherapies and mechanisms of B cell elimination
  • Lupus and AML specific cell humanized mouse models, and how to select to the right model for your research program